ZINFORO is indicated for the treatment of adult (≥ 18 years of age) patients with complicated skin and soft tissue infections (cSSTI) caused by susceptible isolates of the designated microorganism: Staphylococcus aureus (including methicillin-susceptible and -resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca.
Usage: To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftaroline and other antibacterial drugs, ceftaroline should be used to treat only cSSTI that are proven or strongly suspected to be caused by susceptible bacteria. Appropriate specimens for microbiological examination should be obtained in order to isolate and identify the causative pathogens and to determine their susceptibility to ceftaroline. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.